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Nowadays, contrast-enhanced magnetic resonance 
imaging (MRI) is a very important medical tool for the dia-
gnosis of tumorigenic disease. MRI contrast agents used 
as injectable mediums are based chiefly on gadolinium 
because of the significant magnetic signal generated 
by gadolinium chloride hexahydrate (Gd3+) [1]. After in-
jection of the contrast medium, increased blood flow 
to the tumor area results in the accumulation of the agent 
and a concomitantly-enhanced signal upon imaging [2, 
3]. It is well known that the free gadolinium ion is harmful 
to living tissues [4, 5]. To temper such detrimental effects, 
MRI contrast agents have been modified to chelate struc-
tures in order to protect tissues from exposure to the free 
gadolinium ion [6, 7]. However, exposure of mesenchymal 
cells which have a calcium cation sensing receptor, to Gd3+ 
results in stimulation of cell proliferation and mediation 
of increased mitogenic responses [8–10]. Furthermore, 
it has recently been shown that some cancer cell lines — 
myeloma and osteosarcoma in particular — possess 
a similar calcium-sensing receptor [11–13] and myeloma 
cultured lines experience stimulated cell proliferation 
when exposed to Gd3+ [12]. Consequently, MRI contrast 
agents might stimulate the proliferation of these cancer 
cells. To date no published reports have analyzed this 
potential effect.
Our study was conducted with the use of the common 
MRI contrast agent, gadodiamide (Omniscan®), to exami-
ne this possibility by measuring DNA synthesis and the cell 
number of several, commercially available cancer cell lines 
exposed to this MRI contrast agent in vitro.
Culture of cancer cell lines. Human cancer cell lines 
myeloma (RPMI 8226) and osteosarcoma (Saos-2) (ATCC, 
Manassas, VA, USA) were grown in RPMI 1640 and Mc-
Coy’s 5A (ATCC) in a 5% CO2 humidified incubator at 37 ˚ C. 
The culture mediums contained an antibiotic-antimicotic 
solution and 10% (15% for McCoy’s 5A) fetal bovine serum 
(FBS) (Gibco BRL, Guithersburg, MD, USA).
Rat cancer cell line osteosarcoma (UMR-106) 
was purchased from ATCC and grown in Dulbec-
co’s Modified Eagle’s Medium (Gibco BRL) containing 
an antibiotic-antimycotic solution and 10% FBS.
After the initial culture, an adequate number of cells 
were harvested and re-seeded in 96-well culture plates 
at a density of 1000 cells/well and subsequently used 
to measure DNA synthesis. The remaining cells were 
seeded into 24-well plates at a density of 20 000/well 
for determining the cell number.
DNA synthesis. Each cell line was divided into 
six groups on Day 1. Groups 1 to 5 were exposed to ga-
dodiamide (Omniscan®) (Amersham Health, Princeton, 
NJ, USA) (5 µM, 50 µM, 500 µM, 5 mM, 50 mM) in the cul-
ture medium; that is, the 5 mM group was treated with 
10 µl of gadodiamide in 1 ml of culture medium, reflecting 
the rate commonly used in clinical therapeutics. Clinically, 
gadodiamide injected intravenously immediately before 
MRI imaging is diluted from 500 µM to 1 mM within the cir-
culatory system. Group 6 was used as control. Twenty-
four hours after changing the culture medium, 1.0 µCi of 
3H-thymidine (Dupont-NEN, Boston, MA, USA) was added 
to each well, the culture medium was aspirated 18 h there-
after and the cells were washed and collected by detach-
ment with 0.25% trypsin (Gibco BRL). The myeloma cells, 
the cells were harvested onto a 1.2 µm glass filter (What-
man Inc., Clifton, NJ, USA), washed and dried. The rate 
of DNA synthesis was measured with the use of a scintil-
lation counter (Packard Instrument Co., Downers Grove, 
IL, USA). Each experimental group consisted of 5 wells.
Cell number. Using the same experimental protocol 
outlined above, the cell number was counted with a hemo-
cytometer on day 4. The assays were done in quintuple.
Statistical Analysis. Results are expressed 
as the mean ± SD (standard deviation of the mean). 
Assay results were analyzed for differences using 
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analysis of variance (ANOVA) followed by Fisher’s pro-
tected least significant differences (PLSD) test, with 
P-value less than 0.05 considered significant.
Gadodiamide concentrations ranging from 
5 µM to 5 mM induced no stimulation of cell proliferation, 
compared with the control; however, the 50 mM group 
showed marked suppression of cell growth compared 
with the other groups (p < 0.01) (Fig. 1, a). Also, no mor-
phological changes were observed among the groups 
other than in the 50 mM group (Fig. 1, b, c).
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Fig. 1. a, The effect of various concentrations of gadodiamide 
on human myeloma (RPMI8226) cell lines. Cell numbers were 
measured on day 4. Concentrations of gadodiamide ranging 
from 5 µM to 5 mM showed no stimulation of cell proliferation 
compared with the control. The 5 mM group was significantly 
suppressed compared with the other groups (*p < 0.01). Stan-
dard deviation (SD) of the mean is shown by vertical bars. 
The assays were done in quintuple. Morphology of control (b) 
and 500 µM groups (c) on day 4 of cell culture. There were 
no significant morphological changes among the groups, except 
the 50 mM group
DNA synthesis was suppressed in only the 50 mM 
group (p < 0.01) compared with the other groups. There 
were no significant differences among the groups ex-
cept in the 50 mM group (Fig. 2).
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Fig. 2. DNA synthesis after exposure of human myeloma cell line 
RPMI8226 to gadodiamide for 24 h. Concentrations of gadodia-
mide ranging from 5 µM to 5 mM did not show a statistical diffe-
rence in DNA synthesis among the groups. Only the 50 mM group 
showed significant suppression as compared with the other 
groups (*p < 0.01). Standard deviation (SD) of the mean is shown 
by vertical bars. Each assay comprised 5 wells
In both the rat (Fig. 3, a) and human osteosrcoma 
(Fig. 3, b) cell lines, only the 50 mM groups expressed 
suppressed cell growth rates compared with the other 
groups with respect to DNA synthesis. The test groups ex-
posed to gadodiamide concentrations ranging from 5 µM 
to 50 mM did not show stimulation of cell proliferation in ei-
ther of the lines. Survey of the cell number showed the same 
DNA synthesis results for both lines (data not shown).
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Fig. 3. DNA synthesis of rat osteosarcoma cell line UMR-106 (a) 
and of human sarcoma cell line Saos-2 (b) was estimated by expo-
sure of the cells to various concentrations of gadodiamide for 24 h. 
Proliferation rates of only cells exposed to 50 mM gadodiamide 
were suppressed compared with the other groups (*p < 0.01). 
There was no significant difference among the groups, except 
the 50 mM group. Standard deviation (SD) of the mean is shown 
by vertical bars. Each assay comprised 5 wells
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Although administration of an MRI contrast agent 
is very useful in the diagnosis of oncological diseases, 
there are few reports on the effect of contrast agents 
on cancer cells. This may be due to the previous con-
cept that gadolinium is toxic only to normal cells [3, 4]. 
Studies indicate, however, that some cells are activated 
by polyvalent agonists such as Gd3+ binding to their 
cation sensing receptor [7–9]. Myeloma cells being 
one such type [4], a hypothesis has been that MRI con-
trast agents probably stimulate myeloma cell prolifera-
tion. Since 25 µM of Gd3+ has been shown to stimulate 
the proliferation of myeloma cells [12], if gadodiamide 
releases Gd3+ almost completely, then it would be rea-
sonable to assumue that either 5 µM or 50 µM ga-
dodiamide stimulates proliferation of myeloma cells. 
Our study, however, showed that the cultured myeloma 
cell lines were not stimulated by the MRI contrast agent 
as expected. Since cell growth was very high in our as-
say of cell number, the statistical difference among 
the groups except the 50 mM group could not be deter-
mined by only counting the number of myeloma cells. 
Therefore, although measuring DNA synthesis was car-
ried out for the assessment of cell proliferation, the short 
exposure time (24 h) to gadolinium could not show 
evidence of cell proliferation of this cell line. Further 
study is warranted on exposure time of cells to contrast 
agents. Both human and rat osteosarcoma cell lines, 
which possess the same cation receptor as myeloma 
[11], were also not stimulated by gadodiamide. These 
observations suggest that MRI contrast agents are safe 
for use on patients with these types of cancer cells. 
While all cell growth was suppressed by a 50 mM con-
centration, intravenously injected gadodiamide was di-
luted to approximately 500 µM to 1 mM by blood. Thus, 
the 50 mM study group falls well outside the scope 
of reliable analysis. On the other hand, in examina-
tions by MRI angiography, which normally do not relate 
to the diagnosis of tumorigenic disease, a high dose 
of MRI contrast agent is usually required. That 5 mM di-
lution also had no proliferative effect on any cell line 
tested, suggests that doses of up to 5 times normally 
used may not induce significant adverse effects. Fur-
thermore, given that 95–98% of gadodiamide is cleared 
away by 24 h after injection (according to manufacturer 
data), there is probably only a very small amount re-
maining thereafter. This study also showed that pro-
liferation rates of cancer cell lines were not influenced 
by exposure to very small amounts of gadodiamide 
for a short period of time.
Finally, our results show that there is little evidence 
to suggest that commercially available MRI contrast 
agents stimulate proliferation of the tested cancer 
cell lines.
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